See more : DWS Group GmbH & Co. KGaA (0SAY.L) Income Statement Analysis – Financial Results
Complete financial analysis of EQRx, Inc. (EQRXW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EQRx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Heidelberger Druckmaschinen Aktiengesellschaft (HBGRF) Income Statement Analysis – Financial Results
- Delhivery Limited (DELHIVERY.NS) Income Statement Analysis – Financial Results
- SK Inc. (03473K.KS) Income Statement Analysis – Financial Results
- Bunge Limited (BG) Income Statement Analysis – Financial Results
- Armstrong World Industries, Inc. (AWI) Income Statement Analysis – Financial Results
EQRx, Inc. (EQRXW)
About EQRx, Inc.
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 228.50M | 118.11M | 224.39M | 3.44K |
| General & Administrative | 127.38M | 78.27M | 25.69M | 10.44K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 127.38M | 78.27M | 25.69M | 10.44K |
| Other Expenses | -65.00K | 87.05M | 0.00 | 0.00 |
| Operating Expenses | 355.88M | 196.38M | 250.08M | 25.52K |
| Cost & Expenses | 355.88M | 196.38M | 250.08M | 25.52K |
| Interest Income | 25.15M | 436.00K | 97.00K | 0.00 |
| Interest Expense | 25.15M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -161.70M | -7.70M | 338.00K | 171.86K |
| EBITDA | -355.88M | -196.38M | -249.74M | -11.65K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -355.88M | -196.38M | -250.08M | -13.88K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 186.79M | 96.37M | 97.00K | -11.65K |
| Income Before Tax | -169.09M | -100.01M | -249.98M | -25.52K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -374.58M | -9.32M | -97.00K | -11.65K |
| Net Income | 205.49M | -90.69M | -249.89M | -25.52K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.43 | -0.28 | -0.80 | -5.99 |
| EPS Diluted | 0.43 | -0.28 | -0.80 | -5.99 |
| Weighted Avg Shares Out | 474.30M | 324.01M | 311.50M | 4.26K |
| Weighted Avg Shares Out (Dil) | 474.30M | 324.01M | 311.50M | 4.26K |
Source: https://incomestatements.info
Category: Stock Reports